To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
Recruiting now · Early Phase 1
Conditions studied: Multiple Myeloma, Plasma Cell Leukemia
In brief
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human BCMA targeted CAR-NK Cells injection, and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory multiple myeloma or plasma cell leukemia.
Key facts
- Study ID
- NCT06045091
- Run by
- Hrain Biotechnology Co., Ltd.
- People needed
- 18
- Starts
- 2023-07-04
- Expected to finish
- 2027-09-30
- Last updated by the study team
- 2023-09-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Shanghai Changzheng Hospital — Shanghai, Shanghai Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.